Cambridge, MA, United States of America

Joshua Waetzig

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Rigel Pharmaceuticals, Incorporated. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joshua Waetzig. Retrieved from https://idiyas.com/inventor/joshua-waetzig

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 33.3

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Joshua Waetzig: Innovator in Pharmaceutical Chemistry

Introduction

Joshua Waetzig is a notable inventor based in Cambridge, MA, who has made significant contributions to the field of pharmaceutical chemistry. His work primarily focuses on the development of innovative compounds that have the potential to improve therapeutic outcomes.

Latest Patents

Waetzig holds a patent for "Solid forms of pralsetinib." This patent describes the preparation of the compound (cis)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide in various crystalline solid forms and salt forms, each having one or more solid forms. This innovation is crucial for enhancing the stability and efficacy of the compound.

Career Highlights

Joshua Waetzig is currently employed at Rigel Pharmaceuticals, Incorporated, where he continues to advance his research in drug development. His expertise in solid-state chemistry has positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

Waetzig has collaborated with esteemed colleagues such as Gordon D. Wilkie and Lauren Maceachern, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Joshua Waetzig's contributions to pharmaceutical chemistry, particularly through his patent on pralsetinib, highlight his role as an influential inventor in the field. His ongoing work at Rigel Pharmaceuticals continues to pave the way for advancements in drug development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…